Close Menu

NEW YORK – Chinese precision oncology firm Genetron Health said Thursday that it has entered an exclusive licensing agreement with ImmuQuad Biotechnologies to develop and commercialize Seq-MRD, a diagnostic assay for the detection and monitoring of minimal residual disease in select hematologic cancers.

Under the agreement, Genetron gains exclusive, global rights to research, develop, commercialize, and manufacture MRD tests using Seq-MRD, which is an immunogenomics-based method for residual disease detection developed using ImmuQuad's proprietary platform.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Moderna is applying for an Emergency Use Authorization for its coronavirus vaccine, according to the New York Times.

Bloomberg reports AstraZeneca may conduct another study of its candidate SARS-CoV-2 vaccine after dosing error.

The National Health Service is to conduct a trial of Grail's blood-based screening test for cancer.

In PLOS this week: somatic mutation patterns of glioblastomas among Lebanese patients, phenome-wide study using UK Biobank data, and more.